Glasdegib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Glasdegib
Glasdegib.svg
Clinical data
SynonymsPF-04449913
ATC code
Identifiers
CAS Number
ChemSpider
KEGG
ECHA InfoCard100.244.738 Edit this at Wikidata
Chemical and physical data
FormulaC21H22N6O
Molar mass374.45 g·mol−1
3D model (JSmol)

Glasdegib (PF-04449913) is an approved cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is overexpressed in many types of cancer. It inhibits smoothened receptor, as do most drug in its class.[1]

Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib.[2] Another is a combination trial of glasdegib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia.[3] The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.[4] The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.[5]

References[edit]

  1. ^ "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
  2. ^ "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
  3. ^ "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
  4. ^ "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
  5. ^ "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.